ABUS news

Arbutus Biopharma announced that the FDA has lifted the clinical hold on its Investigational New Drug application for AB-101, an oral PD-L1 inhibitor, allowing the company to further evaluate its potential for treating chronic HBV infection.

Arbutus filed plans to repurchase up to US$230M of common stock through a Dutch auction tender offer; proceeds likely stem from revenue.

Genevant will pay Arbutus a $1 million termination fee following the termination of the mRESVIA Agreement as part of the broader patent settlement with Moderna. This action clarifies recovery rights and finalizes terms under the new settlement.

Arbutus Biopharma established a new equity compensation plan enabling grants of stock options, RSUs, and other awards to employees and key personnel. The plan is designed to align employee incentives with shareholder value creation and support long-term talent retention.